DATROWAY ® approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

AstraZeneca and Daiichi Sankyo's TROP2-directed antibody-drug conjugate, DATROWAY (datopotamab deruxtecan-dlnk), has secured accelerated US FDA approval for locally advanced or metastatic EGFR-mutated non-small cell lung cancer in patients who have progressed on prior EGFR-directed therapy and platinum-based chemotherapy. This approval, supported by a 45% objective response rate and 6.5-month duration of response from the TROPION-Lung05 and Lung01 trials, addresses a significant unmet need by offering a novel treatment option for a challenging patient population. Financially, AstraZeneca will pay Daiichi Sankyo a $45 million milestone, with Daiichi Sankyo recognizing US sales for the drug.

Analysis

AstraZeneca and its partner Daiichi Sankyo have secured a significant regulatory win with the US FDA's accelerated approval for DATROWAY in a specific non-small cell lung cancer (NSCLC) population. This approval is a critical milestone, establishing DATROWAY as the first TROP2-directed therapy for lung cancer in the US and addressing a clear unmet need for EGFR-mutated NSCLC patients who have progressed after prior treatments. The approval is based on a 45% objective response rate (ORR) and a 6.5-month median duration of response (DoR) from the TROPION-Lung05 and TROPION-Lung01 trials, providing a solid clinical basis for its use. Financially, the approval triggers a $45 million milestone payment from AstraZeneca to Daiichi Sankyo, with the latter recognizing US sales, a key detail for revenue modeling. However, two material factors temper the outlook: the approval is accelerated and contingent upon benefit verification in a confirmatory trial, and the drug carries significant safety warnings, most notably for severe or fatal interstitial lung disease (ILD)/pneumonitis, which could impact its adoption rate. This approval nonetheless validates the partners' DXd antibody-drug conjugate (ADC) platform and provides positive momentum for the extensive DATROWAY clinical program, which is exploring other indications.

Key Decisions for Investors

• This accelerated approval is a positive catalyst for AstraZeneca, de-risking a key pipeline asset, but investors should note that US sales revenue will be recognized by partner Daiichi Sankyo.
• Monitor the commercial uptake and physician feedback closely, as the drug's significant safety warnings, particularly the risk of fatal ILD/pneumonitis, could limit its market penetration despite strong efficacy data.
• The primary risk remains the contingency of the accelerated approval on a positive confirmatory trial; any negative data from follow-up studies would materially impact the drug's long-term value.
• Attention should be directed towards the broader DATROWAY clinical development program, as future data readouts for other indications in lung and breast cancer represent the next major value inflection points for the franchise.